FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1

Decentralized Clinical Trial Guidance

FDA publishes a guidance on the conduct of clinical trials with decentralized elements.

latest-news-card-1
Human Drugs

CGMP Violations at TJA Health

FDA warns Joliet, IL-based TJA Health about CGMP violations in its manufacturing of finished drugs.

latest-news-card-1
Human Drugs

Quality CDMO Marketing Unapproved Drugs: FDA

FDA warns Fort Worth, TX-based Quality CDMO that it is marketing five unapproved new drugs.

latest-news-card-1
Human Drugs

Consider Phased DSCSA Enforcement: PhRMA

PhRMA asks FDA to consider a phased approach to enforcing the Drug Supply Chain Security Act because many drug company trading partners may not be rea...

latest-news-card-1
Human Drugs

Kisqali Expanded Approval for Early Breast Cancer

FDA approves an expanded use for Novartis Kisqali (ribociclib) combination use with an aromatase inhibitor for the adjuvant treatment of certain peop...

latest-news-card-1
Human Drugs

FDA Lifts Partial Clinical Hold on Alzheimers Drug

FDA lifts a partial clinical hold against Vigil Neuroscience and its ongoing Phase 1 clinical trial of VG-3927, a small molecule targeting human trigg...

Human Drugs

CGMP Violations at Italian Drug Plan

In an untitled letter, FDA says Milan, Italy-based Industria Farmaceutica is manufacturing drugs with CGMP violations.

latest-news-card-1
Human Drugs

FDA Extends Treosulfan NDA Review by 3 Months

Medexus Pharmaceuticals says FDA has extended the review of its Medac licensors resubmitted NDA for treosulfan and its use in allogeneic hematopoietic...

latest-news-card-1
Human Drugs

SSM St. Clare Health Gets FDA-483

FDA issues SSM St. Clare Health Center a 10-observation Form FDA-483 for GMP deficiencies found during an inspection at an outsourcing facility in Fen...

latest-news-card-1
Human Drugs

Guide on Oncology Multiregional Clinical Trials

FDA posts a draft guidance entitled Considerations for Generating Clinical Evidence from Oncology Multiregional Clinical Development Programs (CDP).